167 results about "Coated tablets" patented technology

The invention discloses an atorvaquone enteric-coated tablet, the preparation comprises atorvaquone, glyceryl behenate, teloxpol, a filler, an adhesive, a disintegrating agent and an enteric coating, and the particle size D90 of the atorvaquone is 30-50 [mu] m. The atorvaquone enteric-coated tablet disclosed by the invention is stable and continuous in release and high in bioavailability, can be positioned and released in intestinal tracts and reduce liver circulation, so that the occurrence of phenomena such as liver injury is reduced, the phenomena such as sticking and cracking are avoided in a tabletting process, the quality is qualified and stable, and the dissolution performance and the stability of the atorvaquone enteric-coated tablet are also ensured.

The doxylamine succinate pyridoxine enteric-coated tablet comprises a tablet core and a coating layer, the coating layer comprises a first isolation layer, an enteric-coated layer and a second isolation layer, the materials of the enteric-coated layer comprise a plasticizer, an anti-sticking agent, a defoaming agent and a flexible coating material, and the flexible coating material accounts for 24-28% of the mass of the tablet core. By adding the flexible coating material, the stability of the pharmaceutical preparation is improved, the difference between batches is reduced, the drug dissolution rate reaches 90% or above, and the pharmaceutical preparation can be quickly released.

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).

The invention relates to a pharmaceutical composition in the form of a tablet, said tablet comprising a tablet core, wherein said core comprises benzgalantamine (ALPHA-1062) or salt thereof, and an enteric coating, wherein said enteric coating is configured for dissolution at pH 5.5 and above. Further the invention relates to the pharmaceutical composition for use in the treatment of a brain disease associated with cognitive impairment and / or with a cholinergic deficit. The invention further relates to a method for preparing the pharmaceutical composition.

The invention belongs to the field of pharmaceutical preparations, and provides a gefapison film-coated tablet and a preparation method thereof, the gefapison film-coated tablet contains gefapison or salt thereof, a filler, a disintegrating agent, a flavoring agent, a wetting agent, a lubricant and coating powder, the gefapison film-coated tablet is prepared through a wet granulation process, and the prepared gefapison film-coated tablet is stable in process, qualified in content and good in quality.

The invention relates to a montelukast sodium tablet composition and a preparation method thereof, and belongs to the field of pharmaceutical preparations. The preparation method comprises the following steps: pressing a montelukast sodium micro-tablet and auxiliary material mixed particle by a chip-coated tablet press, wherein the montelukast sodium micro-tablet is used as a tablet core; compared with the prior art, an opacifying agent and a coloring agent are avoided in the prescription composition, the preparation method is innovated, and the quality stability and medication safety of the product are improved.

The invention discloses a preparation method of an anthocyanin gastric floating tablet, which comprises the following steps: firstly obtaining a solution containing a PCA-Fe < 3 + > complex, an anthocyanin solution and a chitosan-acetic acid-sodium alginate mixed solution, and adding the chitosan-acetic acid-sodium alginate mixed solution into the solution containing the PCA-Fe < 3 + > complex under stirring at room temperature to obtain a mixture 1; adding the obtained mixture 1 into an anthocyanin solution to obtain a mixture 2; adding the mixture 2 into a CaCl2 aqueous solution, fully hydrating the obtained mixture 3 in a tablet mold, and freeze-drying to obtain chitosan-sodium alginate gel tablets containing anthocyanin; preparing an HPMC aqueous solution, adding PEG 6000 and sodium bicarbonate to obtain a coating solution, carrying out spray coating on the gel sheet by using the coating solution, and drying to obtain a coated tablet; and carrying out spray coating on the coated tablet by using acrylic resin to obtain the anthocyanin gastric floating tablet. The gastric floating tablet prepared by the invention can realize continuous release of anthocyanin in the stomach.

The invention discloses an estradiol valerate sugar-coated tablet and a preparation method thereof. The estradiol valerate sugar-coated tablet sequentially comprises a tablet core, a powder coating layer, a first sugar coating layer, a coloring layer and a second sugar coating layer from inside to outside, the tablet core contains estradiol valerate; the powder coating layer is prepared from the following components in parts by weight: 1.7 to 3.7 parts of polyethylene glycol 6000, 25 to 35 parts of cane sugar, 0.1 to 0.4 part of povidone K90, 10 to 18 parts of calcium carbonate and 4 to 10 parts of talcum powder. According to the invention, crystallization of cane sugar is effectively inhibited, the surface of a powder coating layer is finer and smoother, the undesirable phenomenon of tablet edge cracking is avoided, and the quality defects of uneven color, color fading and the like caused by moisture absorption are also avoided.

The invention relates to a pharmaceutical composition in the form of a tablet, said tablet comprising a tablet core, wherein said core comprises benzgalantamine (ALPHA-1062) or salt thereof, and an enteric coating, wherein said enteric coating is configured for dissolution at pH 5.5 and above. Further the invention relates to the pharmaceutical composition for use in the treatment of a brain disease associated with cognitive impairment and / or with a cholinergic deficit. The invention further relates to a method for preparing the pharmaceutical composition.

The present invention provides a tablet and a method for manufacturing a tablet that allows for easy formulation of coated tablets, even when calcium carbonate is used for coating the tablet. [Solution] A tablet coated with a coating layer, wherein the coating layer comprises calcium carbonate granules and a binder for binding the calcium carbonate granules together. The invention also provides a method for manufacturing a tablet coated with a coating layer, comprising a raw material preparation step of dispersing calcium carbonate granules and a binder for binding the calcium carbonate granules together in an aqueous medium to obtain a coating raw material, and a coating layer formation step of coating a tablet with the coating raw material.

The invention addresses the instability and toxicity of organometallic compounds used as fuel additives, which can pose environmental and health risks during handling. While these additives improve fuel combustion, efficiency, and reduce emissions by increasing octane, their handling exposes humans and the environment. This invention provides a formulation, coating process (spraying, immersion, extrusion, powder coating), and testing method to prevent direct contact. Coatings, comprising organic hydrocarbons, do not hinder octane enhancement, ensure deposit-free release in fuel tanks, and clean the fuel system. The coating also prevents sublimation during storage. Performance is evaluated by measuring weight loss under vacuum.

The invention discloses a mixed auxiliary material for traditional Chinese medicine film coated tablets and a preparation method of the mixed auxiliary material. The mixed auxiliary material comprises the following components in percentage by weight: 50-60% of etherified crosslinked starch, 15-20% of pregelatinized starch, 10-15% of sodium carboxymethyl starch, 0.6-0.8% of magnesium stearate and 2-3% of talc. The etherified cross-linked starch is used for replacing a traditional polymer, a cross-linked structure of the etherified cross-linked starch blocks water molecule permeation, pre-gelatinized starch improves powder fluidity, crushed talcum powder is mixed with the pre-gelatinized starch, microgaps are filled, a friction system is reduced, and the situation that the sheet surface is rough and prone to sticking is avoided; the dynamic balance of sodium carboxymethyl starch and magnesium stearate ensures the synergism of disintegration and lubrication, and completely avoids the problems of poor tablet hardness, slow disintegration and large weight difference of traditional Chinese medicine film-coated tablets.

A gastro-resistant high-strength unit dosage form includes a solid solution prepared by hot-melt extrusion, whereby the solid solution contains 300 mg posaconazole and an enteric polymer in a specific weight ratio. The unit dosage form may be a capsule or an optionally film-coated tablet.

The invention relates to the technical field of biological medicine, in particular to an ilaprazole enteric-coated tablet and a preparation method thereof. The ilaprazole enteric-coated tablet sequentially comprises a tablet core, an isolating layer and an enteric-coated layer from inside to outside, the tablet core at least comprises an active ingredient ilaprazole or a pharmaceutically acceptable salt thereof, the particle size D90 of the ilaprazole or the pharmaceutically acceptable salt thereof is less than or equal to 10 microns, and a solvent used in a coating process of the isolating layer is water. By controlling the particle size D90 of the ilaprazole to be less than or equal to 10 microns and controlling the preparation method of the tablet core, the tablet core with relatively good content uniformity and appearance state is prepared, the problem that the tablet core is easy to generate spots is solved, and the problem that the intestinal tract is stimulated by over-high local drug concentration when the ilaprazole enteric-coated tablet is released and dissolved out is avoided. In the coating process of the isolating layer, solvent purified water is used for replacing traditional ethanol, so that the problems of pressure for removing an organic solvent in the preparation process of the tablet and environmental pollution in the preparation process are avoided under the condition of ensuring the quality of the tablet.

The invention belongs to the technical field of proton pump inhibition medicine preparations, and relates to a rabeprazole sodium enteric-coated tablet and a preparation method thereof. The technical problems that an existing rabeprazole sodium enteric-coated tablet is insufficient in stability, lagged in dissolution and the like are solved. The enteric-coated tablet consists of a tablet core and an enteric-coated coating layer wrapped outside the tablet core, wherein the tablet core comprises auxiliary materials such as rabeprazole sodium, a filling agent, an adhesive, a stable dissolution promoter and the like; the enteric coating layer comprises an enteric coating material, a plasticizer, an anti-sticking agent and a solvent. Through the synergistic effect of the compound stabilizer and process control, the stability and dissolution performance of the enteric-coated tablet are synergistically improved, meanwhile, the production process is simplified, and the preparation method is suitable for industrial application.

The present invention belongs to the technical field of pharmaceutical formulations, specifically relates to a controlled-release tablet of loxoprofen sodium, its preparation method, and use. The controlled-release tablet comprises a drug-containing immediate-release layer, a drug-containing core layer, and a drug-containing sustained-release layer, the drug-containing core layer comprising a plain tablet core, an enteric coating film, and a sealing coating film. The preparation method includes granulating the raw materials for the drug-containing immediate-release layer and the drug-containing sustained-release layer, respectively, wet granulating the raw materials for the plain tablet core and compressing them into tablets, followed by sequentially applying a first sealing coating, a second enteric coating, and a third sealing coating to obtain a drug-containing core, placing the drug-containing core on the drug-containing sustained-release layer granules and pre-compressing them, and then placing the drug-containing immediate-release layer granules on the pre-compressed tablet, compressing them, and coating them to obtain the drug-containing core. The present invention achieves the sustained-release effect of the loxoprofen sodium tablet core by designing the single-layer structure, raw materials, and coating layer components of the dry-coated tablet, thereby achieving 12-hour in vivo efficacy and improving patient compliance.

The utility model relates to the technical field of health care product preparation devices, in particular to a health care tablet coating device which comprises an equipment box body, a feeding port is formed in the right end of the equipment box body, and a coating module is arranged in the equipment box body. The coating module comprises a transmission plate, a supporting rod, a supporting ring, a positioning groove, a coating roller, a fixing ring, a positioning sliding block, a spraying pipe and an air inlet pipe, an inserting hole is formed in the center of the transmission plate, a driving module is arranged on the left side of the equipment box body, and the driving module comprises a first positioning ring, a servo motor, a transmission gear, a second positioning ring and a transmission gear ring. One group of coating rollers is fed into the equipment box body, the other group of coating rollers are fed into the equipment box body, then the tablets coated in the previous group of coating rollers are taken out, and the inner walls of the coating rollers are cleaned, so that the cleanliness of the interiors of the coating rollers is effectively kept, the coating quality is improved, and meanwhile, the multiple groups of coating rollers are matched, so that the coating efficiency is improved. The feeding and discharging time is shortened, and the coating efficiency is improved.

The invention provides a bromocriptine mesylate enteric-coated tablet and a preparation method thereof. Specifically, the bromocriptine mesylate enteric-coated tablet comprises a tablet core and an enteric coating layer wrapping the tablet core. The enteric-coated tablet disclosed by the invention is simple in process, good in stability and small in gastrointestinal side effect, the bioavailability of the enteric-coated tablet is more than two times that of a common tablet sold in the market, the dosage is expected to be reduced, the side effect is further reduced, and the enteric-coated tablet has excellent clinical value.

1. The name of the design product: packaging box (omeprazole enteric-coated tablets). 2. The use of the design product: used for the outer packaging of products. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: the unfolded state reference drawing.

The invention belongs to the technical field of medicines, and relates to an estradiol valerate film-coated tablet and a preparation method thereof. The estradiol valerate sugar film-coated tablet comprises the following components in percentage by mass: 60%-80% of an estradiol valerate tablet core and 20%-40% of a water-based sugar film coating, the water-based sugar film coating comprises a powder coating layer and a coloring layer. The preparation method of the estradiol valerate film-coated tablet comprises the following steps: preheating the estradiol valerate tablet core; coating with a powder coating layer; drying the coated tablet of the estradiol valerate powder coating layer; coating a coloring layer; and drying and cooling the estradiol valerate coloring layer coated tablet to obtain the estradiol valerate sugar film coated tablet. According to the estradiol valerate sugar film-coated tablet and the preparation method thereof provided by the invention, the coating process is simple and efficient, and the stability of related substances of a preparation can be ensured while the process is optimized.

The invention discloses a rifapentine isoniazide tablet and a preparation method thereof, the rifapentine isoniazide tablet is a core-coated tablet, and comprises an inner-layer tablet core containing rifapentine and an outer-layer tablet layer containing isoniazide; the inner-layer tablet core comprises rifapentine, edetate disodium, sodium ascorbate and lauryl sodium sulfate, the rifapentine accounts for 53-63% of the total mass of the inner-layer tablet core, and the rifapentine tablet further comprises a filler, a stabilizer, a disintegrating agent, an adhesive, a surfactant, a lubricant and a coating layer; the coating layer coats the inner-layer tablet core; the outer sheet layer comprises isoniazide, a filling agent, a disintegrating agent, an adhesive, a lubricant and an adhesive; and the mass of the isoniazide accounts for 75-95% of the total mass of the outer sheet layer. According to the rifapentine isoniazide tablet disclosed by the invention, the compliance of a patient is enhanced. And meanwhile, the potential safety hazard problem of impurity increase caused by incompatibility of rifapentine and isoniazide is solved.

This application discloses a jujube seed and Ganoderma lucidum film-coated tablet and its preparation method. The film-coated tablet uses jujube seed and Ganoderma lucidum in a weight ratio of (2.9–3.1):2 as active raw materials, employs a microcrystalline cellulose and erythritol compound as fillers, and combines them with silica, magnesium stearate, and a specific composite film-coating agent. The preparation method includes raw material pretreatment, water extraction, vacuum concentration, vacuum drying, fluidized bed granulation, total mixing and tableting, and film coating, optimizing each process parameter. This application solves the technical problems of existing traditional Chinese medicine extracts, such as high hygroscopicity, poor compressibility, poor stability, and unclear synergistic effects. The prepared product has high active ingredient content, good stability, rapid disintegration, and good patient compliance, making it suitable for large-scale industrial production and possessing good market application prospects.

This utility model relates to the technical field of coating devices, specifically a coating device for the enteric coating layer of bisacodyl enteric-coated tablets. It includes a cabinet with a roller inside. A rotating ring is connected to the left side wall of the cabinet, and the left end of the rotating ring is rotatably connected to the inner left side wall of the cabinet via a bearing. In operation, bisacodyl tablets are placed into the roller, the door is closed, and a motor drives the drive wheel, transmission belt, driven wheel, rotating ring, and roller to rotate. Support rollers provide support and improve the stability of the roller's rotation. A peristaltic pump draws and delivers the coating solution to the nozzle of a spray gun. The spray gun is connected to a compressed air pipeline, and the compressed air is used to evenly spray the coating solution onto the surface of the bisacodyl tablets for coating. The rotation of the roller causes the tablets to continuously rotate, ensuring the uniformity of the coating solution spray, thereby effectively coating the surface of the bisacodyl tablets with an enteric coating layer.

The invention discloses an artemisia selengensis leaf extract self-microemulsifying drug delivery system and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The system is composed of artemisia selengensis leaf extract and a self-microemulsion drug delivery system composed of an oil phase, a surfactant and a cosurfactant, and the mass ratio of the oil phase to the surfactant to the cosurfactant is (10-20): (60-80): (10-30). According to the invention, the liquid system is solidified into powder through an adsorption carrier, and the powder is further prepared into enteric-coated tablets. The drug delivery system can significantly improve the solubility, stability and intestinal absorption efficiency of caffeoylquinic acid compounds (CQAs) in the artemisia selengensis leaves, effectively inhibits degradation of the caffeoylquinic acid compounds in gastric juice, shows excellent xanthine oxidase inhibitory activity, can be used for preparing functional foods or drugs for reducing uric acid, and realizes high-valued utilization of artemisia selengensis leaf resources.

The invention relates to a coating method of a powerful anti-glare sugar-coated tablet. The coating method comprises the following steps: coating an isolating layer; coating a mixed slurry layer; coating a sugar coating layer; according to the preparation method disclosed by the invention, a novel mixed slurry coating method is adopted, the simple syrup and the talcum powder are prepared into mixed slurry, and the mixed slurry is uniformly dripped in a production process by using an automatic dripping method of a coating gun, so that the non-uniformity of manually scattering the talcum powder is reduced, the production operation is simple and convenient, the coating difficulty is reduced, and the operation error rate is reduced; the quality risk of an intermediate product is reduced, dust flying and pollution to the production environment in the production process are avoided, and the weight increment of the coating is reduced. According to the method, the use amount of talcum powder is only 1 / 2 of that of a traditional method, and the rejection rate of cut pieces is reduced to 2%-3% from 4%-5% of that of the original method.

The invention discloses a galanthamine hydrobromide enteric-coated tablet and a preparation method thereof. The tablet is composed of a tablet core, an isolation layer and an enteric layer, the tablet core contains 5.0%-16.0% of galanthamine hydrobromide, and auxiliary materials such as mannitol, a mixture of magnesium stearate and sodium stearyl fumarate in a specific proportion, colloidal silicon dioxide and the like are matched; the isolating layer adopts an opadry II type film coating, and the enteric-coated layer adopts an opadry Acryl-EZE II type enteric-coated coating. The dissolution rate of the tablet in an acidic medium with the pH value of 1.2 for 2 hours is less than 5%, the release rate of the tablet in a medium with the pH value of 5.5 or 6.8 for 45 minutes is more than or equal to 80%, the tablet is sealed and placed at 40 DEG C + / -2 DEG C / 75% + / -5% RH for 6 months, the stability is good, and the pharmacokinetic parameters are excellent. The preparation method comprises the steps of raw and auxiliary material pretreatment, graded premixing, total mixing and lubricating, tabletting, two-step coating and the like, and the process is stable and controllable. The enteric-coated tablet disclosed by the invention is strong in targeted release property, high in stability and good in bioavailability, and can guarantee the effectiveness and safety of medication.

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).

The invention discloses an in-vitro dissolution method of a posaconazole enteric-coated tablet, which is characterized in that a Tween-80 (TWEEN-80) surfactant is added into a dissolution medium, so that the solubility of the posaconazole enteric-coated tablet in a phosphate buffer solution is remarkably improved, the phenomenon that a solution in a dissolution cup is not uniform is solved, the jump point phenomenon of a dissolution curve is eliminated, and the dissolution rate of the posaconazole enteric-coated tablet is improved. When a phosphate buffer solution added with a certain amount of surfactant is used as a dissolution medium, the accumulated dissolution amount at each time point is stable, the dissolution curve is smooth, the detection result is accurate and reliable, the repeatability and predictability of the dissolution test are remarkably improved, and a more reliable detection method is provided for the initial stage of drug research and development and quality control.

A coating composition useful for coating a tablet such as a tablet, a capsule, a pill, a capsule, a confection or a grain, the coating composition comprising an opaque amount of cross-linked povidone having an average particle size of less than 10 [mu] m. Crosslinked povidone having an average particle size of less than 10 [mu] m is used as an opacifier and white pigment in the coating of the coated tablet in place of titanium dioxide.

The present invention relates to a tablet press discharging device and a preparation process for diclofenac sodium enteric-coated tablets. The tablet press discharging device comprises: a discharging slot is provided with a feed port and a discharging port, the bottom of the slot is inclined downward along the discharging direction, the discharging slot pivots at least three springs that rotate between a first position and a second position, the springs are interlaced and divide the discharging slot into a primary division chamber and at least two subdivision chambers along the discharging direction, the slot bottoms of the primary division chamber and the subdivision chamber are both provided with a group of sieve holes, the diameter of the sieve holes is smaller than the diameter of the tablets, and the springs are arranged on one side of each group of sieve holes close to the discharging port; the dust collecting mechanism corresponds to the sieve holes, including a powder collecting box and a dust collector, the powder collecting box is arranged below the sieve holes, and the dust collector is connected to the powder collecting box through a pipeline; when the spring is in the first position, the tablets are intercepted by the spring; when the spring is in the second position, the tablets are released and slide toward the discharging port. The discharging device of the present invention can timely and effectively remove the drug powder so that the tablet coating effect is highly uniform.